WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Revealed: Brit tourist, 19, subjected to sex attack in Majorca 'was gangBiden says Brown v. Board of Education ruling was about more than educationA warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue itStudent fatally shot, suspect detained at Georgia's Kennesaw State UniversityBella Hadid goes braless in a thighBiden says Brown v. Board of Education ruling was about more than educationBaby Reindeer's realMystery artist who erected signs comparing potholeThe government wants to buy their floodWith Djokovic awaiting the winner, Murray trails Hanfmann at rain
2.5103s , 5260.3671875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Worldly Wonders news portal